Prolyl hydroxylase inhibitors

Abstract

The invention described herein relates to certain quinoline-8-carboxamide derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

Description

technical field The present invention relates to certain quinoline-8-carboxamide derivatives which are inhibitors of HIF prolyl hydroxylase and thus have use in the treatment of diseases which would benefit from inhibition of this enzyme (anemia is an example) . Background of the invention Anemia occurs when red blood cells are low or abnormal, which leads to low oxygen levels in the blood. Anemia is commonly seen in cancer patients, especially those receiving chemotherapy. Anemia is commonly observed in people older than middle age, in patients with renal disease, and in a wide range of diseases associated with chronic disease. Generally, anemia is caused by decreased production of erythropoietin (Epo), which prevents erythropoiesis (maturation of red blood cells). Epo production can be increased by inhibition of prolyl hydroxylase, which regulates hypoxia-inducible factor (HIF). One strategy to increase erythropoietin (Epo) production is to stabilize and thereby incr...

AI Technical Summary

Problems solved by technology

Thus, inhibition of prolyl hydroxylase leads to increased levels of HIF-α, which increases Epo production

Images